Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 12-Jul-24 6:22 PM View:  | Coulie Bernard President and CEO Director | Pliant Therapeutics, Inc. (PLRX) | 10-Jul-24 | Market Sale | 38,710 | $11.56 | $447,488.00 | (4%) 930.96K to 892.25K | (2%) |
| 12-Jul-24 6:41 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 10-Jul-24 | Market Sale | 9,900 | $11.56 | $114,444.00 | (4%) 269.19K to 259.29K | (2%) |
| 12-Jul-24 6:15 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 10-Jul-24 | Market Sale | 7,656 | $11.56 | $88,503.40 | (8%) 101.7K to 94.04K | (2%) |
| 12-Jul-24 6:37 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 10-Jul-24 | Market Sale | 10,911 | $11.56 | $126,131.00 | (4%) 293.03K to 282.12K | (2%) |
| 12-Jul-24 6:45 PM View: | Lefebvre Eric Chief Medical Officer | Pliant Therapeutics, Inc. (PLRX) | 10-Jul-24 | Market Sale | 12,319 | $11.56 | $142,408.00 | (5%) 225.37K to 213.05K | (2%) |
| 11-Jul-24 4:54 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 09-Jul-24 | Grant | 21,313 | -- | -- | 8% 271.71K to 293.03K | |
| 11-Jul-24 5:01 PM View: | Lefebvre Eric Chief Medical Officer | Pliant Therapeutics, Inc. (PLRX) | 09-Jul-24 | Grant | 24,063 | -- | -- | 12% 201.31K to 225.37K | |
| 11-Jul-24 4:47 PM View: | Coulie Bernard President and CEO Director | Pliant Therapeutics, Inc. (PLRX) | 09-Jul-24 | Grant | 75,625 | -- | -- | 9% 855.34K to 930.96K | |
| 11-Jul-24 4:58 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 09-Jul-24 | Grant | 19,337 | -- | -- | 8% 249.85K to 269.19K | |
| 11-Jul-24 4:41 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 09-Jul-24 | Grant | 14,954 | -- | -- | 17% 86.75K to 101.7K | |
| 06-May-24 6:02 AM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 02-May-24 | Option Exercise | 21,000 | $2.08 | $43,680.00 | 8% 250.71K to 271.71K | |
| 24-Jan-24 4:56 PM View: | Coulie Bernard President and CEO Director | Pliant Therapeutics, Inc. (PLRX) | 23-Jan-24 | Grant | 128,150 | -- | -- | 18% 725.7K to 853.85K | |
| 24-Jan-24 4:57 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 23-Jan-24 | Grant | 55,250 | -- | -- | 28% 194.6K to 249.85K | |
| 24-Jan-24 4:57 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 23-Jan-24 | Grant | 31,500 | -- | -- | 15% 216.86K to 248.36K | |
| 24-Jan-24 4:57 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 23-Jan-24 | Grant | 31,500 | -- | -- | 57% 55.25K to 86.75K | |
| 24-Jan-24 4:57 PM View: | Cheung Lily Chief Human Resource Officer | Pliant Therapeutics, Inc. (PLRX) | 23-Jan-24 | Grant | 26,000 | -- | -- | 3270% 0.8K to 26.8K | |
| 24-Jan-24 4:58 PM View: | Lefebvre Eric Chief Medical Officer | Pliant Therapeutics, Inc. (PLRX) | 23-Jan-24 | Grant | 42,900 | -- | -- | 27% 156.92K to 199.82K | |
| 19-Jan-24 5:18 PM View: | Lefebvre Eric Chief Medical Officer | Pliant Therapeutics, Inc. (PLRX) | 17-Jan-24 | Private Sale | 10,295 | $17.23 | $177,383.00 | (6%) 167.22K to 156.92K | |
| 19-Jan-24 5:19 PM View: | Coulie Bernard President and CEO Director | Pliant Therapeutics, Inc. (PLRX) | 17-Jan-24 | Private Sale | 25,721 | $17.23 | $443,173.00 | (3%) 751.42K to 725.7K | |
| 19-Jan-24 5:19 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 17-Jan-24 | Private Sale | 9,786 | $17.23 | $168,613.00 | (4%) 226.65K to 216.86K | |
| 19-Jan-24 5:11 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 17-Jan-24 | Private Sale | 5,197 | $17.23 | $89,544.30 | (9%) 60.44K to 55.25K | |
| 19-Jan-24 5:19 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 17-Jan-24 | Private Sale | 9,781 | $17.23 | $168,527.00 | (5%) 204.39K to 194.6K | |
| 07-Aug-23 8:50 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 04-Aug-23 | Option Exercise | 8,791 | $2.08 | $18,285.30 | 4% 237.91K to 246.7K | |
| 07-Aug-23 8:50 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 04-Aug-23 | Sale (Planned) | 20,050 | $20.01 | $401,200.00 | (8%) 246.7K to 226.65K | |
| 07-Aug-23 8:50 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 03-Aug-23 | Option Exercise | 1,800 | $2.08 | $3,744.00 | < 1% 247.37K to 249.17K | |
| 07-Aug-23 8:50 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 03-Aug-23 | Planned Option Sale | 8,791 | $20.00 | $175,820.00 | (4%) 250.97K to 242.18K | |
| 07-Aug-23 8:50 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 03-Aug-23 | Sale (Planned) | 4,278 | $20.00 | $85,560.00 | (2%) 242.18K to 237.91K | |
| 07-Aug-23 8:50 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 03-Aug-23 | Planned Option Sale | 1,800 | $20.00 | $36,000.00 | < 1% 249.17K to 250.97K | |
| 21-Jul-23 4:40 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 20-Jul-23 | Private Sale (Planned) | 4,755 | $17.55 | $83,450.20 | (7%) 65.2K to 60.44K | |
| 19-Jul-23 8:26 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 17-Jul-23 | Private Sale | 17,937 | $18.01 | $323,029.00 | (7%) 268.91K to 250.97K | |
| 19-Jul-23 8:29 PM View: | Lefebvre Eric Chief Medical Officer | Pliant Therapeutics, Inc. (PLRX) | 17-Jul-23 | Private Sale | 22,321 | $18.01 | $401,981.00 | (12%) 189.54K to 167.22K | |
| 19-Jul-23 8:31 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 17-Jul-23 | Private Sale | 12,778 | $18.01 | $230,120.00 | (16%) 77.98K to 65.2K | |
| 19-Jul-23 8:20 PM View: | Coulie Bernard President and CEO Director | Pliant Therapeutics, Inc. (PLRX) | 17-Jul-23 | Private Sale | 70,150 | $18.01 | $1,263,340.00 | (9%) 821.57K to 751.42K | |
| 19-Jul-23 8:23 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 17-Jul-23 | Private Sale | 19,771 | $18.01 | $356,058.00 | (9%) 223.77K to 204.0K | |
| 18-Jul-23 7:14 PM View: | Coulie Bernard President and CEO Director | Pliant Therapeutics, Inc. (PLRX) | 14-Jul-23 | Grant | 137,500 | -- | -- | 20% 684.07K to 821.57K | |
| 18-Jul-23 7:22 PM View: | Lefebvre Eric Chief Medical Officer | Pliant Therapeutics, Inc. (PLRX) | 14-Jul-23 | Grant | 43,750 | -- | -- | 30% 145.79K to 189.54K | |
| 18-Jul-23 7:26 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 14-Jul-23 | Grant | 27,187 | -- | -- | 54% 50.79K to 77.98K | |
| 18-Jul-23 7:19 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 14-Jul-23 | Grant | 35,156 | -- | -- | 15% 233.75K to 268.91K | |
| 18-Jul-23 7:17 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 14-Jul-23 | Grant | 38,750 | -- | -- | 21% 185.02K to 223.77K | |
| 14-Jun-23 6:14 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 13-Jun-23 | Option Exercise | 30,750 | $2.08 | $63,960.00 | 20% 154.27K to 185.02K | |
| 12-Jun-23 6:19 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 09-Jun-23 | Option Exercise | 5,800 | $2.08 | $12,064.00 | 4% 148.47K to 154.27K | |
| 03-Apr-23 7:07 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 03-Apr-23 | Sale (Planned) | 2,877 | $26.79 | $77,066.20 | (5%) 53.67K to 50.79K | |
| 03-Apr-23 6:51 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 30-Mar-23 | Private Sale | 9,036 | $26.52 | $239,643.00 | (4%) 242.79K to 233.75K | |
| 03-Apr-23 7:01 PM View: | Lefebvre Eric Chief Medical Officer | Pliant Therapeutics, Inc. (PLRX) | 30-Mar-23 | Private Sale | 11,245 | $26.52 | $298,228.00 | (7%) 157.03K to 145.79K | |
| 03-Apr-23 6:46 PM View: | Coulie Bernard President and CEO Director | Pliant Therapeutics, Inc. (PLRX) | 30-Mar-23 | Private Sale | 35,339 | $26.52 | $937,222.00 | (5%) 719.41K to 684.07K | |
| 03-Apr-23 6:48 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 30-Mar-23 | Private Sale | 9,960 | $26.52 | $264,148.00 | (6%) 158.43K to 148.47K | |
| 03-Apr-23 7:07 PM View: | Ouimette Mike General Counsel & Corp. Sec'y | Pliant Therapeutics, Inc. (PLRX) | 30-Mar-23 | Private Sale | 4,874 | $26.52 | $129,263.00 | (8%) 58.54K to 53.67K | |
| 31-Mar-23 5:59 PM View: | Hull Hans Chief Business Officer | Pliant Therapeutics, Inc. (PLRX) | 29-Mar-23 | Grant | 17,578 | -- | -- | 8% 225.21K to 242.79K | |
| 31-Mar-23 5:56 PM View: | Cummings Keith Lamont Chief Financial Officer | Pliant Therapeutics, Inc. (PLRX) | 29-Mar-23 | Grant | 19,375 | -- | -- | 14% 139.06K to 158.43K | |
| 31-Mar-23 5:54 PM View: | Coulie Bernard President and CEO Director | Pliant Therapeutics, Inc. (PLRX) | 29-Mar-23 | Grant | 68,749 | -- | -- | 11% 650.66K to 719.41K |
